Meeting
2022 ASCO Annual Meeting
Chemotherapy refusal and subsequent survival in older women with high genomic risk, estrogen receptor–positive breast cancer.
Authors
McKenzie White
University of Minnesota, Minneapolis, MN
McKenzie White , Saranya Prathibha , Corinne Praska , Madison Kolbow , Jacob Ankeny , Christopher James LaRocca , Eric Hans Jensen , Todd M. Tuttle , Schelomo Marmor , Jane Yuet Ching Hui
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 520)
DOI
10.1200/JCO.2022.40.16_suppl.520
Abstract #
520
Poster Bd #
292
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Predicting epirubicin response in Danish patients with breast cancer.
First Author: Ida Kappel Buhl
Poster
2023 ASCO Annual Meeting
Associations of frailty with overall survival (OS) and functional decline among older adults with non–small-cell lung cancer (NSCLC) receiving chemotherapy, immunotherapy, and/or targeted therapy.
First Author: Howard Jinsoo Lee Jr.
Poster
2023 ASCO Annual Meeting
Treatment at twilight: Is less more in the management of octogenarians with non-small cell lung cancer (NSCLC)?
First Author: Ethan Burns
Poster
2023 ASCO Annual Meeting
Comparative overall survival of patients in trials of CKD4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.
First Author: Coralea Kappel